Objective: The purpose of this study was to evaluate the impact of hypokalemia on hypertension outcomes in patients with aldosterone-producing adenoma (APA) after adrenalectomy and to determine the factors affecting complete hypertension cure in a large series. Methods: Characteristics from 376 APA patients treated with adrenalectomy between 2005 and 2011 were collected from our center. Factors affecting complete hypertension cure were assessed using logistic regression. Results: At the end of follow-up, 207 (55.05%) patients were completely cured, whereas 138 (36.7%) patients were improved, and 31 (8.3%) patients remain refractory. Age (p = 0.028), >2 antihypertensive agents (p < 0.001), duration of hypertension (p < 0.001), duration of hypokalemia (p = 0.037), systolic blood pressure (p = 0.016), and level of plasma aldosterone (p < 0.001) were associated with hypertension outcomes in univariate analysis. However, multivariate logistic regression analysis showed that only duration of hypertension ≥6 years (OR = 0.496, 95% CI 0.323-0.762, p = 0.001) and level of plasma aldosterone ≥35 ng/dl (OR = 0.503, 95% CI 0.326-0.776, p = 0.002) were the significantly independent factors affecting complete hypertension cure. Conclusions: This is the largest series to show that only duration of hypertension and level of plasma aldosterone were the factors affecting complete hypertension cure after adrenalectomy for APA. This study highlights the importance of early diagnosis and early adrenalectomy.

Keywords:
Primary aldosteronism, Hypertension, Adrenalectomy, Adrenal gland
1.
Conn JW: Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955;45:3-17.
2.
Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al: Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008;371:1921-1926.
3.
Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al: A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300.
4.
Steichen O, Zinzindohoué F, Plouin PF, Amar L: Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res 2012;44:221-227.
5.
Lumachi F, Ermani M, Basso SM, Armanini D, Iacobone M, Favia G: Long-term results of adrenalectomy in patients with aldosterone-producing adenomas: multivariate analysis of factors affecting unresolved hypertension and review of the literature. Am Surg 2005;71:864-869.
6.
Meyer A, Brabant G, Behrend M: Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 2005;29:155-159.
7.
Waldmann J, Maurer L, Holler J, Kann PH, Ramaswamy A, Bartsch DK, Langer P: Outcome of surgery for primary hyperaldosteronism. World J Surg 2011;35:2422-2427.
8.
van der Linden P, Steichen O, Zinzindohoué F, Plouin PF: Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study. J Hypertens 2012;30:761-769.
9.
Utsumi T, Kawamura K, Imamoto T, Kamiya N, Komiya A, Suzuki S, et al: High predictive accuracy of Aldosteronoma Resolution Score in Japanese patients with aldosterone-producing adenoma. Surgery 2012;151:437-443.
10.
Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, et al: The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 2008;247:511-518.
11.
Giacchetti G, Ronconi V, Rilli S, Guerrieri M, Turchi F, Boscaro M: Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma. Eur J Endocrinol 2009;160:639-646.
12.
Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, et al: Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009;54:665-673.
13.
Trésallet C, Salepçioglu H, Godiris-Petit G, Hoang C, Girerd X, Menegaux F: Clinical outcome after laparoscopic adrenalectomy for primary hyperaldosteronism: the role of pathology. Surgery 2010;148:129-134.
14.
Murashima M, Trerotola SO, Fraker DL, Han D, Townsend RR, Cohen DL: Adrenal venous sampling for primary aldosteronism and clinical outcomes after unilateral adrenalectomy: a single-center experience. J Clin Hypertens (Greenwich) 2009;11:316-323.
15.
Kim RM, Lee J, Soh EY: Predictors of resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenoma. J Korean Med Sci 2010;25:1041-1044.
16.
Mourad JJ, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME: Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. Am J Hypertens 2008;21:742-747.
17.
Rayner B: Primary aldosteronism and aldosterone-associated hypertension. J Clin Pathol 2008;61:825-831.
18.
Rossi GP, Pessina AC: Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 2009;27:656-657.
19.
Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, et al: Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009;94:869-875.
20.
Gaddam KK, Pimenta E, Husain S, Calhoun DA: Aldosterone and cardiovascular disease. Curr Probl Cardiol 2009;34:51-84.
21.
Wang B, Zhang G, Ouyang J, Deng X, Shi T, Ma X, et al: Association of DNA polymorphisms within the CYP11B2/CYP11B1 locus and postoperative hypertension risk in the patients with aldosterone-producing adenomas. Urology 2010;76:1018.e1-1018.e7.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.